(RTTNews) - On Monday, Standard BioTools Inc. (NASDAQ: LAB) announced that it has signed a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on the healthcare industry.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.